Why Researchify Health Has Incredible Impact
Digestive and autoimmune GI conditions often flare unpredictably, making timing—and trust—critical. Many eligible patients are never informed about trials or disengage after a single outreach. Researchify Health uses human-like SMS to educate, pre-screen, and coordinate next steps based on symptoms, medications, and readiness. Sites keep the patient relationship while our flows simplify eligibility, reduce incomplete submissions, and sustain interest through flare–remission cycles.
Key Benefits for Gastroenterology
Timing that matches symptoms
Automated check-ins re-engage patients when eligibility changes (post-flare or medication adjustments).
Polypharmacy made manageable
Structured SMS captures multi-med regimens and contraindications early to avoid disqualifying surprises.
Awareness to action
Many IBD/IBS patients never hear about relevant trials; plain-language, low-pressure texts turn interest into next steps.
Cleaner pre-screens
Guided question sets reduce incomplete or inconsistent submissions—improving screening efficiency.
Inclusive communication
Multilingual messaging supports patients with limited health literacy and diverse backgrounds.
Large, distributed population
Two-way SMS reaches 70M+ Americans with digestive diseases—no portals or cold calls required.
Meet Jane
70M+
Americans with digestive diseases
<1%
Current participation rate
60%+
Experience fluctuating symptoms
<15%
IBD patients informed of trials
40%
Reduction in incomplete submissions
80+
Languages supported
Challenges We Address
High disease burden: More than 70 million Americans live with digestive diseases, yet clinical trial participation remains below 1%
Symptom variability: 60%+ of GI patients experience fluctuating symptoms that make one-time screening unreliable. Automated nudges re-check eligibility when status changes.
Medication complexity: Many patients take multiple daily medications; missing details lead to disqualifications. Structured SMS collects regimens, doses, and recent changes up front.
Awareness deficit: Fewer than 15% of eligible IBD patients report being informed of a trial opportunity. Plain-language education and links move patients from curiosity to pre-screen.
Incomplete pre-screening: Traditional methods can produce up to 40% incomplete submissions. Guided prompts and reminders increase completion and accuracy.
Health-literacy barriers: Complex terminology and portals deter participation. Multilingual, concise messages and step-wise instructions meet patients where they are.